Mechelen

• Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF … Ended recruitment
  2023-507964-38-00 5 2022-09-01 Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutate
• A study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-s … Ended recruitment
  2023-503868-16-00 5 2022-02-14 Small-Cell Lung Cancer (SCLC)
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination with other Anti-Cancer Therap … Ended recruitment
  2023-506311-18-00 1 2021-06-29 Advanced or metastatic solid tumors with KRAS G12C mutation
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• Efficacy and Safety of Erenumab in Pediatric Subjects with Episodic Migraine Ended recruitment
  2023-504930-23-00 5 2019-07-19 Episodic Migraine
• Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended recruitment
  2023-504820-24-00 5 2018-03-21 Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
• Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, immunogenicity and safety of one dose of … Ended
  2024-520354-37-00 4 2025-09-08 Influenza disease
• A trial to learn how safe AZD8630 is and how well it works in adults with uncontrolled asthma. Ended
  2024-514228-18-00 4 2025-01-16 Asthma in adults who remain uncontrolled despite medium to high dose I
• A Study to Assess the Effectiveness and Safety of Taplucainium Inhalation Powder (NOC-110) in Adults with Refractory or Unexplained Chronic … Ended
  2024-515026-86-00 4 2024-12-18 Refractory or Unexplained Chronic Cough
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended
  2024-511057-22-00 5 2024-12-04 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended
  2024-511557-21-00 5 2024-11-14 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Influenza Vaccine Compared with a Licensed Influenza … Ended
  2024-516240-26-00 5 2024-10-11 Influenza
• A study on the immune response and safety of a vaccine against respiratory syncytial virus (RSV) when given alone and together with a vaccin … Ended
  2023-510196-59-00 5 2024-06-15 Respiratory Syncytial Virus Infections
• Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended
  2022-502899-23-00 5 2024-04-23 Hepatic Encephalopathy (OHE)
• A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants with Cirrhosis-ZEAL-UNLOCK Ended
  2023-506893-11-00 4 2024-04-19 Cirrhosis of the liver is a condition in which the liver is scarred an
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)
• A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended
  2023-503315-15-00 4 2023-12-20 Thrombolysis of symptomatic proximal vein thrombosis
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadr … Ended
  2023-504168-40-00 5 2023-11-06 Prevention of invasive extraintestinal pathogenic Escherichia coli (Ex
• A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety, and reactogenicity of respirat … Ended
  2022-501988-40-00 5 2023-08-17 RSV-associated (subtypes A and B) disease in adults aged 60 years of a
• A study to find and confirm the dose and assess the safety, reactogenicity and immune response of a vaccine against influenza in healthy you … Ended
  2022-502308-66-00 7 2023-04-27 Healthy volunteers (prevention of influenza infection)
• Primary carE PPi dEprescRibing (PEPPER) trial Ended
  2022-502375-37-00 6 2023-04-16 heartburn
• A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une … Ended
  2024-513460-26-00 5 2023-03-29 Refractory Chronic Cough, Including Unexplained Chronic Cough
• A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Un … Ended
  2023-505211-21-00 4 2023-03-10 Previously untreated locally advanced or metastatic non-small cell lun

Showing 49–72 of 81 trials